Genovis AB (publ.)
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a GENO.ST research report →
Companywww.genovis.com
Genovis AB (publ. ) designs, develops, and sells tools for development of drugs for customers in the pharmaceutical and medical device industries. The company offers FabALACTICA, a cysteine protease that digests human IgG1; FabRICATOR, an enzyme that primarily digests the hinge region of IgG; and FabRICATOR Z, an enzyme for the digestion of mouse IgG2a and IgG3, as well as for generating a homogenous pool of F(ab')2 and Fc fragments.
- CEO
- Fredrik Olsson
- IPO
- 2008
- Employees
- 32
- HQ
- Kävlinge, SE
Price Chart
Valuation
- Market Cap
- $1.34B
- P/E
- 55.05
- P/S
- 10.28
- P/B
- 4.82
- EV/EBITDA
- 36.46
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 89.52%
- Op Margin
- 15.88%
- Net Margin
- 18.67%
- ROE
- 9.25%
- ROIC
- 5.29%
Growth & Income
- Revenue
- $128.95M · -1.08%
- Net Income
- $23.50M · -28.61%
- EPS
- $0.36 · -28.00%
- Op Income
- $27.49M
- FCF YoY
- -100.00%
Performance & Tape
- 52W High
- $29.80
- 52W Low
- $15.64
- 50D MA
- $19.04
- 200D MA
- $20.75
- Beta
- 1.70
- Avg Volume
- 78.22K
Get TickerSpark's AI analysis on GENO.ST
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Our GENO.ST Coverage
We haven't published any research on GENO.ST yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate GENO.ST Report →